Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group
Menée en Turquie dans un contexte de vie réelle à partir de données portant sur 285 patientes atteintes d'un cancer du sein triple négatif de stade localement avancé et non résécable ou de stade métastatique, cette étude évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité du sacituzumab govitécan
Sacituzumab govitecan (SG) is an antibody–drug conjugate approved for metastatic or unresectable locally advanced triple-negative breast cancer (mTNBC) after at least two prior systemic therapies, yet real-world evidence remains limited. We conducted a retrospective, multicenter study including 285 patients with unresectable locally advanced or metastatic TNBC treated with SG across 52 oncology centers in Turkey. Median progression-free and overall survival were 5.4 months (95% confidence interval [CI], 4.6–6.2) and 12.2 months (95% CI, 10.5–13.9), respectively, with a 12-month overall survival rate of 49.2%. The objective response rate and disease control rate in evaluable patients were 36.8% and 63.9%. Grades 3–4 adverse events, mainly neutropenia, occurred in 44.2% of patients. Dose reductions were needed in 20% of cases; no treatment-related deaths were reported. Our large real-world cohort reinforces the effectiveness and manageable safety profile of SG, mirroring pivotal trials, and highlights its value as a therapeutic option in diverse and heavily pretreated mTNBC populations.
International Journal of Cancer , résumé, 2025